The latest update is out from Eco Animal Health ( (GB:EAH) ).
ECO Animal Health Group has announced a planned leadership transition as Dr. Andrew Jones will retire as Chairman of the Board on March 31, 2025, to be succeeded by Dr. Joachim Hasenmaier. Dr. Hasenmaier, who joined the Board as a Non-executive Director in 2024, has extensive experience in the animal health industry, previously leading transformation initiatives at Boehringer Ingelheim. This change is part of a strategic move to enhance ECO’s focus on commercializing its R&D pipeline, aiming to drive growth and deliver value for its stakeholders.
More about Eco Animal Health
ECO Animal Health is a leading global company in animal health, specializing in the development and marketing of veterinary pharmaceuticals, particularly antibiotics and vaccines for pigs and poultry. Headquartered in the UK, the company boasts a significant R&D pipeline and has marketing authorizations in over 70 countries, employing over 200 people worldwide. Their flagship product, Aivlosin®, is a patented medication effective against respiratory and intestinal diseases in pigs and poultry.
YTD Price Performance: -9.15%
Average Trading Volume: 56,624
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £43.7M
For an in-depth examination of EAH stock, go to TipRanks’ Stock Analysis page.